Functionally active hepatitis B virus (HBV) DNA is open and accessible, while the action of an epigenetic editor turns it into functionally inactive DNA, which is closed and inaccessible. Chroma Medicine Inc. has presented data regarding their epigenetic editor CRMA-1001, which is delivered by lipid nanoparticles.
Chengdian (Suzhou) Biopharmaceutical Co. Ltd. has received IND clearance from the FDA, allowing it to initiate a first-in-human phase I trial of CD-001.
CDR-Life Inc. has reported preclinical data for the CDR-813, a novel antibody fragment-based bivalent T-cell engager targeting preferentially expressed antigen in melanoma (PRAME) on HLA-A*02:01.
Rakuten Medical Inc. has presented preclinical results with RM-0256, a PD-L1-targeted photoimmunotherapy, showing its ability to kill immunosuppressive myeloid cells to activate local and systemic antitumor immunity.
The management of obesity and its associated comorbidities needs novel approaches for safety and efficacy. Researchers from Pep2tango Therapeutics Inc. are aiming to face this challenge by developing an approach that promotes superior weight loss through the loss of fat mass only, while preserving the muscle lean mass.
By treating mice with antifibrotic drugs, researchers were able to stave off functional decline of the ovaries. Six weeks of systemic treatment with the antifibrotic pirfenidone, which is approved for the treatment of idiopathic pulmonary fibrosis, in early middle age improved both the morphology and the endocrine function of the animals’ ovaries at 1 year of age.
Guangdong HEC Pharmaceutical Co. Ltd. has described programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) interaction inhibitors reported to be useful for the treatment of cancer, infections and autoimmune disease.
Scientists at Centre National de la Recherche Scientifique, Ecole Nationale Supérieure de Chimie de Paris, Universitat de Barcelona and Université Paris Sciences et Lettres have divulged metal complexes (particularly Ru[II]) acting as photosensitizers for photodynamic therapy reported to be useful for the treatment of cancer, dermatological disorders and fungal infections.
Japan Tobacco Inc. has identified NLRP3 inflammasome inhibitors reported to be useful for the treatment of arteriosclerosis, gout, inflammatory bowel disease, amyotrophic lateral sclerosis, multiple sclerosis, metabolic dysfunction-associated steatohepatitis (MASH; formerly nonalcoholic steatohepatitis [NASH]), Alzheimer’s disease and Parkinson’s disease.
RSS
